Lacosamide: no dose adjustment is considered necessary in patients with mild or moderate renal impairment. A maximum dose of 300 mg/day should not be exceeded in patients with severe renal ...
Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic ...